Overview of treatment patterns for platinum-sensitive relapsed ovarian cancer in Austria
Non-interventional, Multicenter, Prospective Register Study to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer (ROC) Patients in Austria
This study looks at how women in Austria with relapsed ovarian cancer are being treated after their first relapse to see what treatments they choose and how well those treatments work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | Female |
| Sponsor | Medical University Innsbruck Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 9 sites (Graz and 8 other locations) |
| Trial ID | NCT04369352 on ClinicalTrials.gov |
What this trial studies
This observational register aims to document the treatment patterns of women with platinum-sensitive relapsed epithelial ovarian cancer in Austria. Patients who have experienced their first relapse after at least six months from the last platinum-based chemotherapy will be invited to participate. Data will be collected over a 24-month period, including patient demographics, treatment choices, and reasons for those choices. The study will also track subsequent recurrences and treatment outcomes to provide insights into the management of this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 or older who have experienced their first platinum-sensitive relapse of ovarian, peritoneal, or fallopian tube cancer.
Not a fit: Patients who do not speak or understand German or who cannot provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of treatment choices and outcomes for patients with platinum-sensitive relapsed ovarian cancer.
How similar studies have performed: While this study focuses on treatment patterns, similar observational studies have provided valuable insights into cancer management, suggesting potential for meaningful findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women aged 18 years or older * Presence of first platinum-sensitive ROC (ovarian, peritoneal and/or fallopian tube cancer) * Must have received at least 4 cycles of chemotherapy during primary therapy * At time of inclusion a treatment for ROC must be planned * Patients must not have more than 1 prior line of chemotherapy * Signed informed consent Exclusion Criteria: * No knowledge of spoken and written German * Signed informed consent is not given
Where this trial is running
Graz and 8 other locations
- Medical University Graz — Graz, Austria (Recruiting)
- Medical University Innsbruck — Innsbruck, Austria (Recruiting)
- Bezirkskrankenhaus Kufstein — Kufstein, Austria (Recruiting)
- LKH Hochsteiermark — Leoben, Austria (Recruiting)
- Bezirkskrankenhaus Lienz — Lienz, Austria (Recruiting)
- Kepler Universitätsklinikum Linz — Linz, Austria (Recruiting)
- Ordensklinikum Linz — Linz, Austria (Recruiting)
- Krankenhaus der Barmherzigen Schwestern Ried — Ried Im Innkreis, Austria (Recruiting)
- Medical University Vienna — Vienna, Austria (Recruiting)
Study contacts
- Principal investigator: Lukas Hefler, Prim. Dr. — Ordensklinikum Linz
- Study coordinator: AGO Studienzentrale
- Email: ago.studienzentrale@i-med.ac.at
- Phone: 0043 512 504 24132
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.